Universe Pharmaceuticals Inc. (UPC) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
UPC Revenue Growth
UPC Revenue Analysis (2018–2025)
As of May 7, 2026, Universe Pharmaceuticals Inc. (UPC) generated trailing twelve-month (TTM) revenue of $40.9 million, reflecting significant decline in growth of -14.1% year-over-year. The most recent quarter (Q4 2025) recorded $8.7 million in revenue, down 4.9% sequentially.
Looking at the longer-term picture, UPC's 5-year compound annual growth rate (CAGR) stands at -10.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $48.0 million in 2021.
When compared to Healthcare sector peers including HCWB (-87.9% YoY), XTLB, and NUVB (+1205.5% YoY), UPC has underperformed the peer group in terms of revenue growth. Compare UPC vs HCWB →
UPC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UPCCurrent | $41M | -14.1% | -10.3% | -16.3% | |
 HCWB | $3M | -87.9% | - | -1148.5% | |
 XTLB | $451,000 | - | - | -481.6% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 CPRX | $589M | +19.8% | +37.7% | 43.8% | |
 TLPH | $28,000 | - | -65.1% | -48157.1% |
UPC Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $17.9M | -22.4% | $6.3M | 35.3% | $-2,915,919 | -16.3% |
| 2024 | $23.0M | -28.7% | $6.1M | 26.4% | $-8,019,840 | -34.8% |
| 2023 | $32.3M | -19.5% | $10.3M | 31.9% | $-3,526,774 | -10.9% |
| 2022 | $40.1M | -16.3% | $21.9M | 54.5% | $-7,019,445 | -17.5% |
| 2021 | $48.0M | +56.3% | $25.3M | 52.8% | $13.6M | 28.3% |
| 2020 | $30.7M | -7.6% | $14.1M | 45.9% | $10.3M | 33.4% |
| 2019 | $33.2M | +16.5% | $13.4M | 40.3% | $9.8M | 29.4% |
| 2018 | $28.5M | - | $13.4M | 47.0% | $9.7M | 33.9% |
See UPC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UPC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UPC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUPC — Frequently Asked Questions
Quick answers to the most common questions about buying UPC stock.
Is UPC's revenue growth accelerating or slowing?
UPC revenue declined -14.1% year-over-year, contrasting with the 5-year CAGR of -10.3%. TTM revenue fell to $41M. This reverses the prior growth trend.
What is UPC's long-term revenue growth rate?
Universe Pharmaceuticals Inc.'s 5-year revenue CAGR of -10.3% reflects the variable expansion pattern. Current YoY growth of -14.1% is below this long-term average.
How is UPC's revenue distributed by segment?
UPC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.